2020 American Transplant Congress
Utilization of Organs from Donors Exposed to Hepatitis C: ? Standard of Care
*Purpose: To report the results of a clinical program to utilize livers and kidneys from donors exposed to Hepatitis C.*Methods: We initially started to explore…2020 American Transplant Congress
Viral Kinetics of De Novo HCV Infection and Response to Antiviral Therapy in Liver and Kidney Transplant Recipients Receiving HCV-Viremic Donors
*Purpose: There is general agreement that expanded use of organs from HCV-viremic donors is desirable, including in recipients without HCV infection. However, the optimal treatment…2020 American Transplant Congress
Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
*Purpose: Genotype 4 HCV is the most common genotype in Saudi Arabia and the Middle East. Management of HCV has shifted in the last few…2020 American Transplant Congress
Glecaprevir-Pibrentasvir Effect on Tacrolimus Troughs in Abdominal Transplant Recipients
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Glecaprevir-pibrentasvir (GP) is one of several pangenotypic therapies available for the treatment of hepatitis C. Historical use of ritonavir based hepatitis C therapies increased…2020 American Transplant Congress
Association between Ezetimibe Usage and Hepatitis C RNA Levels in Uninfected Kidney Transplant Recipients Who Received Hepatitis C Infected Kidneys
James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN
*Purpose: Our previous data showed that transplantation of kidneys from hepatitis C virus (HCV) infected donors to HCV negative recipients achieved excellent short-term graft function,…2020 American Transplant Congress
Single Center Experience of Valganciclovir and Adjunctive CMV IVIG for the Treatment of CMV Infection in Lung Transplant Recipients
*Purpose: Cytomegalovirus(CMV) infection happens commonly and causes significant morbidity in lung transplant (LTx) recipients. The use of CMV hyperimmune globulin (CMVIg) as an adjunctive treatment…2019 American Transplant Congress
Burden of Respiratory Syncytial Disease among Hospitalized Immunocompromised Adults
Northwestern University Comprehensive Transplant Center, Chicago, IL
*Purpose: Respiratory syncytial virus (RSV) is associated with significant mortality amongst hematopoietic stem cell transplant (HSCT) and lung transplant recipients. Although RSV is responsible for…2019 American Transplant Congress
A CMV Vaccine Based on Non-Replicating Lymphocytic Choriomeningitis Virus Vectors Expressing gB and pp65 is Safe and Immunogenic in Healthy Volunteers and Entering a Phase 2 Trial in Kidney Transplant Recipients
*Purpose: Cytomegalovirus (CMV) is a significant pathogen in pregnancy and immunocompromised patients. Antiviral prophylaxis is limited by toxicities, recurrent infection, and resistance. A safe and…2019 American Transplant Congress
Reduction in Waitlist Time Using HCV Positive Liver Grafts in HCV Negative Recipients
Ochsner Health System, New Orleans, LA
*Purpose: With direct-acting antiviral (DAA) therapy, we feel that HCV+ organs are safe for all patients regardless of their HCV status and have adopted a…2019 American Transplant Congress
Early Achievement of Sustained Virological Response in Liver Transplant Recipients with Hepatitis C Reduces Risks of End Stage Renal Disease
*Purpose: Chronic kidney disease (CKD) is common after liver transplantation (LT) and result worse morbidity and mortality. Hepatitis C virus (HCV) infection is recognized as…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 14
- Next Page »